Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan launching "authorized" generic Procardia XL

Executive Summary

Mylan will begin selling versions of all three dosage strengths of nifedipine extended-release tablets supplied by Pfizer under a patent litigation settlement. Pfizer is expected to begin shipping the product to Mylan the week of March 20. Mylan received approval in December for a 30 mg dose but launch was delayed pending litigation (1"The Pink Sheet" Dec. 20, 1999, In Brief). Mylan will pay royalties to TIMERx controlled-release technology developer Penwest on sales of the 30 mg dose. Pfizer licenses the hypertension and angina treatment from Bayer. A suit against Mylan by Bayer, which manufactures the product in Europe as Adalat, has yet to be resolved. However, Mylan notes the company will be entitled to market the applicable products supplied by Pfizer "irrespective of the fate of its litigation with Bayer"
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS035700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel